Need for infliximab dose intensification in Crohn's disease and ulcerative colitis (original) (raw)

Clinical Gastroenterology and Hepatology, 2006

First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis

Satoshi Motoya

Journal of gastroenterology, 2015

View PDFchevron_right

Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response

Luis Abreu

Gastroenterología y hepatología

View PDFchevron_right

Infliximab for induction and maintenance therapy for ulcerative colitis

William Sandborn

New England Journal …, 2005

View PDFchevron_right

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis

William Sandborn

Gastroenterology, 2014

View PDFchevron_right

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease

Martin Bortlik

Journal of Crohn's and Colitis, 2013

View PDFchevron_right

Success and safety of high infliximab trough levels in inflammatory bowel disease

Joško Osredkar

Scandinavian journal of gastroenterology, 2018

View PDFchevron_right

Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort

Joshua Korzenik

Inflammatory bowel diseases, 2015

View PDFchevron_right

Long-Term Outcome Of Patients With Ulcerative Colitis And Primary Non-Response To Infliximab

Gerassimos Mantzaris

Journal of Crohn's & colitis, 2016

View PDFchevron_right

Review and clinical perspectives for the use of infliximab in ulcerative colitis

Craig Render, Hillary Steinhart, L. Dieleman

Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2008

View PDFchevron_right

Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice

Antonio Tursi

European review for medical and pharmacological sciences, 2010

View PDFchevron_right

Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients

Sven Almer

Alimentary Pharmacology & Therapeutics, 2016

View PDFchevron_right

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

Marc Ferrante

Gut, 2008

View PDFchevron_right

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience

Bruce Salzberg MD, FACG

Inflammatory Bowel Diseases, 2018

View PDFchevron_right

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update

Garrett Lawlor

Clinical and Experimental Gastroenterology, 2009

View PDFchevron_right

Predictors of early response to infliximab in patients with ulcerative colitis

Ilse Hoffman

Inflammatory Bowel Diseases, 2007

View PDFchevron_right

Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response

JUAN ANTONIO OBREGON MENDOZA

Journal of Clinical Gastroenterology, 2011

View PDFchevron_right

Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up

Michele Cicala

World journal of gastroenterology : WJG, 2007

View PDFchevron_right

Mo1915 – Long-Term Outcomes of Infliximab Therapy for Japanese Patients with Crohn’s Disease At Different Times of Initiation of Infliximab Administration

Satoshi Motoya

Gastroenterology

View PDFchevron_right

Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

Herma Fidder

Gut, 2009

View PDFchevron_right

Need for infliximab dose intensification in Crohn's disease and ulcerative colitis (original) (raw)

Related papers